NCT04742634View on ClinicalTrials.gov

Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

May 12, 2022

Primary Completion Date

November 30, 2033

Study Completion Date

November 30, 2033

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

DEC-C

"* DEC-C will be provided by Taiho Pharmaceuticals.~* Cycle 1 Day 1 may take place between Day 42 \& Day 100 post-transplant."

DEVICE

MyeloSeq-HD

-Laboratory test developed at Washington University School of Medicine

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

Taiho Oncology, Inc.

INDUSTRY

lead

Washington University School of Medicine

OTHER